Potential new drug to mitigate SARS-CoV-2 infection consequences

Researchers at the University of Malaga study how '4-PBA' treatment modulates the inflammatory response in severe cases of COVID-19
18-Sep-2020 10:55 AM EDT, by University of Malaga

Newswise — Scientists from the Department of Cell Biology of the University of Malaga (UMA) and the Andalusian Centre for Nanomedicine and Biotechnology (BIONAND) have made progress in finding new rapid implementation therapies to combat the COVID-19 pandemic, identifying a new drug that could prevent or mitigate the consequences derived from SARS-CoV-2 infection.

In the coming year, a team led by the researchers of the UMA Iván Durán and Fabiana Csukasi will study how 4-Phenylbutiric acid (4-PBA) treatment modulates the inflammatory response produced in severe cases of COVID-19. The project has been financed by the COVID-19 Fund of the Government of Andalusia, with an initial endowment of EUR 90,000 and the possibility of a three-year renewal. First results have already been published in the scientific journal Cytokine and Growth Factors Review.

The inflammatory process identified in severe cases of coronavirus causes an uncontrolled and excessive release of cytokines -molecules in charge of organizing the body's defenses- which could even trigger vascular hyperpermeability and multiorgan failure. Controlling such cytokine "storm", through those controlling them, that is, the infected cells, is precisely what these researchers of the UMA propose.

"When cells are stressed by infection, they call the cytokines, and the more stressed they are, the more persistent they become, provoking this uncontrolled inflammation. Hence, one possible treatment for COVID-19 is to reduce cellular stress", explains Durán.

According to the researcher, repurposing the 4-PBA anti-stress drug, approved for clinical use against other diseases and, hence, easy to apply clinically, could modulate such cellular stress, which is also present in pathologies like diabetes, aging or carcinogenesis, which, in turn, are classified as risk factors for COVID-19.

Identifying risk groups

"Our preliminary results conducted on animal models have demonstrated that 4-PBA fully curbs mortality caused by respiratory failure derived from cellular stress", says the professor of the UMA, who further explains that these first studies have also identified the endoplasmic reticulum resident protein "BiP" (Binding Immunoglobulin Protein) -a stress blood marker- as indicator of cellular stress situations, likely to be explored and measured in affected patients.

This way, as Durán points out, BiP levels, apart from determining the efficacy of 4-PBA treatment, could serve as early indicators of COVID-19 risk groups, establishing a correlation between high levels and the inflammatory severity after the viral infection.

"There are people already suffering from diseases that cause cellular stress, and when they become infected with coronavirus, they are more likely to fall ill or die. Therefore, if we know that the patient suffers from cellular stress, we can kill two birds with one stone: we can detect susceptibility before infection occurs and know how to treat it in due time", remarks the scientist of the UMA. In order to confirm the effectiveness and security of 4-PBA treatment through in vitro and in vivo studies of cytokine storm and SARS-CoV-2 infection, the scientists Csukasi and Durán work at the Biomedical Research Institute of Malaga (IBIMA) in collaboration with Dr. José María Reguera and Dr. Javier Sánchez from the Regional University Hospital of Malaga and Virgen de la Victoria University Hospital, respectively, and Deborah Krakow, researcher of the University of California, Los Angeles, as well as the researchers Manuel Mari-Beffa, Gustavo Rico, José Miguel Tejeiro, Rick Visser and David Bagllieto, members of the Bioengineering and Tissue Regeneration Laboratory (LABRET), directed by Professor José Becerra, who are also members of the Cellular Therapy Network, CIBER-BBN and CIBER-NED.

###

SEE ORIGINAL STUDY




Filters close

Showing results

110 of 3817
Released: 30-Oct-2020 6:35 PM EDT
UCLA Health infectious disease experts tout critical role mask wearing plays in limiting spread of COVID-19
University of California, Los Angeles (UCLA), Health Sciences

With thousands of new cases logged daily and a vaccine to fight COVID-19 still in development, UCLA Health infectious disease experts are encouraging people to continue to wear masks as the best method of protecting against virus transmission.

Released: 30-Oct-2020 5:35 PM EDT
Surgeon General expects COVID-19 vaccine to be available by year’s end
University of California, Los Angeles (UCLA), Health Sciences

In a wide-ranging talk with UCLA Health physicians, Wednesday, Oct. 28, United States Surgeon General Jerome Adams, MD, MPH, addressed the politicization of the pandemic and the means of containing the spread of COVID-19. He also offered hope that a vaccine for the virus will be available by year’s end.

Released: 30-Oct-2020 4:15 PM EDT
Study shows myocarditis linked to COVID-19 not as common as believed
Louisiana State University Health Sciences Center - New Orleans

A study conducted by Richard Vander Heide, MD, PhD, Professor and Director of Pathology Research at LSU Health New Orleans School of Medicine, and Marc Halushka, MD, PhD, Professor of Pathology at Johns Hopkins University School of Medicine, suggests myocarditis caused by COVID-19 may be a relatively rare occurrence.

access_time Embargo lifts in 2 days
Embargo will expire: 3-Nov-2020 11:00 AM EST Released to reporters: 30-Oct-2020 3:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 3-Nov-2020 11:00 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: 247373_web.jpg
Released: 30-Oct-2020 2:30 PM EDT
Researcher develops app to reach Black community with COVID-19 information
University of Cincinnati

A University of Cincinnati cardiologist is partnering with researchers in St. Louis and rural Georgia to develop a smartphone app that will deliver COVID-19 information and education that is targeted toward Black communities.

Newswise: 247467_web.jpg
Released: 30-Oct-2020 1:55 PM EDT
SARS-CoV-2 might attack red marrow and block new erythrocytes formation
Far Eastern Federal University

Specialists from the Department of Fundamental Medicine of Far Eastern Federal University (FEFU) with Russian and Japanese colleagues have probed into mechanisms of COVID-19 inside-the-body distribution linked to erythrocytes damaging. According to researchers, the virus might attack red marrow, thus being detrimental not only for erythrocytes in the bloodstream but also for the process of the formation of the new ones.

Released: 30-Oct-2020 12:40 PM EDT
Government of Canada awards $2.5M to McMaster University to support the COVID-19 border study with McMaster HealthLabs
McMaster University

McMaster University has been awarded $2.5 million from the Government of Canada to support the McMaster HealthLabs (MHL) Canadian International COVID-19 Surveillance Border Study at Toronto Pearson International Airport, being run in partnership with Air Canada and the Greater Toronto Airports Authority (GTAA).

Released: 30-Oct-2020 12:00 PM EDT
5 Big Questions on Health Care and COVID-19
University of Virginia Darden School of Business

The coronavirus pandemic has once again thrust the unusual state of American health care into the spotlight. With a presidential election that could have a dramatic impact on the state of health care for millions on 3 November, Professor Vivian Riefberg considers the state of the industry.

Newswise: Infection by Confection: COVID-19 and the Risk of Trick-or-Treating
Released: 30-Oct-2020 11:05 AM EDT
Infection by Confection: COVID-19 and the Risk of Trick-or-Treating
University of California San Diego Health

Researchers determined that COVID-19 transmission risk via Halloween candies is low, even when they are handled by infected people, but handwashing and disinfecting collected sweets reduces risk even further.

Newswise:Video Embedded third-spike-in-covid-19-cases-plus-the-vaccine-trials-live-expert-panel-for-october-29-3pm-edt
VIDEO
Released: 30-Oct-2020 9:40 AM EDT
TRANSCRIPT AND VIDEO AVAILABLE: "Third spike" in COVID-19 cases, plus the vaccine trials: Live Expert Panel for October 29
Newswise

"Third spike" in COVID-19 cases, plus the vaccine trials: Live Expert Panel for October 29, 3PM EDT


Showing results

110 of 3817

close
1.32013